Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2016-12-07

Last Posted Date: 2024-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 351

Registration Number: NCT02985957

Locations: 🇺🇸
Local Institution - 0078, Albany, New York, United States
🇺🇸
Local Institution - 0010, Philadelphia, Pennsylvania, United States
🇩🇰
Local Institution - 0063, Aarhus N, Midtjylland, Denmark

and more 56 locations

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Phase 3

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2016-11-10

Last Posted Date: 2022-05-12

Lead Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Target Recruit Count: 196

Registration Number: NCT02961257

Locations: 🇫🇷
CHU Henri-Mondor, Créteil, France
🇫🇷
Hôpital Universitaire Tenon, Paris, France
🇫🇷
Institut de Cancérologie du Gard - CHU, Nîmes, France

and more 28 locations

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Phase 3

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Placebo
Drug: ibrutinib
Drug: Prednisone

First Posted Date: 2016-11-09

Last Posted Date: 2023-03-30

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 193

Registration Number: NCT02959944

Locations: 🇺🇸
Emory University, Winship Cancer Institute /ID# 1140-0033, Atlanta, Georgia, United States
🇺🇸
Stanford University/Stanford Cancer Center, Pasteur Drive /ID# 1140-0400, Stanford, California, United States
🇺🇸
Loyola University /ID# 1140-0713, Maywood, Illinois, United States

and more 99 locations

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: enzalutamide
Drug: abiraterone acetate
Drug: prednisone

First Posted Date: 2016-11-09

Last Posted Date: 2024-12-09

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 900

Registration Number: NCT02960022

Locations: 🇫🇷
Site FR33021, Bordeaux Cedex, France
🇺🇸
Site US10052, Anchorage, Alaska, United States
🇺🇸
Site US10011, Tucson, Arizona, United States

and more 232 locations

Ustekinumab for the Treatment of Giant Cell Arteritis

Phase 1

Terminated

Conditions: Giant Cell Arteritis
Temporal Arteritis
Horton's Disease

Interventions: Drug: Ustekinumab
Drug: Prednisone

First Posted Date: 2016-11-04

Last Posted Date: 2020-06-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 13

Registration Number: NCT02955147

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

Phase 4

Completed

Conditions: Immunosuppression

Interventions: Drug: Tacrolimus Extended Release Capsule
Drug: Mycophenolate mofetil
Drug: Prednisone
Drug: Mycophenolate Sodium

First Posted Date: 2016-11-03

Last Posted Date: 2019-12-26

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 25

Registration Number: NCT02953873

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

Not Applicable

Completed

Conditions: Immunosuppression

Interventions: Drug: Tacrolimus
Drug: Prednisone
Drug: Everolimus
Drug: Mycophenolate mofetil

First Posted Date: 2016-11-03

Last Posted Date: 2019-12-24

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 40

Registration Number: NCT02954198

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Phase 1

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Decitabine

First Posted Date: 2016-11-01

Last Posted Date: 2020-03-11

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 58

Registration Number: NCT02951728

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Phase 2

Recruiting

Conditions: Stage II Prostate Adenocarcinoma
Stage III Prostate Adenocarcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Androgen Receptor Antagonist ARN-509
Other: Quality-of-Life Assessment
Biological: Gonadotropin-releasing Hormone Analog
Drug: Prednisone
Other: Questionnaire Administration
Procedure: Radical Prostatectomy

First Posted Date: 2016-10-31

Last Posted Date: 2023-09-26

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 90

Registration Number: NCT02949284

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Niraparib
Drug: Apalutamide
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2016-10-05

Last Posted Date: 2020-07-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT02924766

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy